000 04267nam a22004815i 4500
001 978-1-60327-829-4
003 DE-He213
005 20140220084512.0
007 cr nn 008mamaa
008 130607s2010 xxu| s |||| 0|eng d
020 _a9781603278294
_9978-1-60327-829-4
024 7 _a10.1007/978-1-60327-829-4
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
100 1 _aFigg, William D.
_eeditor.
245 1 0 _aDrug Management of Prostate Cancer
_h[electronic resource] /
_cedited by William D. Figg, Cindy H. Chau, Eric J. Small.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2010.
300 _aXVII, 428p. 34 illus., 22 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aCell Biology of Prostate Cancer and Molecular Targets -- Cell Biology of Prostate Cancer and Molecular Targets -- Hormone Therapy -- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer -- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer -- Androgens and Prostate Cancer -- Androgen Receptor Biology in Prostate Cancer -- Androgen Receptor Antagonists -- 5-Alpha Reductase Inhibitors in Prostate Cancer -- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer -- Androgen Deprivation Therapy -- Pharmacogenetics of the Androgen Metabolic Pathway -- Chemotherapy -- Mitoxantrone -- Docetaxel -- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer -- Platinum Agents in Prostate Cancer -- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer -- Microtubule Targeting Agents -- Angiogenesis -- Principles of Antiangiogenic Therapy -- Bevacizumab in Advanced Prostate Cancer -- Thalidomide and Analogs -- Investigational Angiogenesis Inhibitors -- Pharmacogenetics of Angiogenesis -- Bone Metastasis -- Pathophysiology of Prostate Cancer Bone Metastasis -- Radiopharmaceuticals -- Bisphosphonates for Prevention and Treatment of Bone Metastases -- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer -- Calcitriol and Vitamin D Analogs -- Immunotherapy -- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches -- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer -- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX -- CTLA-4 Blockade for Prostate Cancer Treatment -- Prevention -- Prostate Cancer Chemoprevention Strategies -- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk -- Inflammation as a Target in Prostate Cancer -- Drug Development -- Challenges for the Development of New Agents in Prostate Cancer -- FDA Approval of Prostate Cancer Treatments -- Applications of Proteomics in Prostate Cancer -- Erratum to: Docetaxel -- Erratum to: Docetaxel.
520 _aThis book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry
650 0 _aMedicine.
650 0 _aInternal medicine.
650 0 _aOncology.
650 0 _aUrology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aUrology/Andrology.
650 2 4 _aInternal Medicine.
700 1 _aChau, Cindy H.
_eeditor.
700 1 _aSmall, Eric J.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781603278317
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-60327-829-4
912 _aZDB-2-SME
999 _c110800
_d110800